

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **APPOINTMENTS OF GENERAL MANAGER AND VICE GENERAL MANAGERS**

### **1. INTRODUCTION**

The board of directors (“**Board**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) announces that:

- (a) Mr. Li Hong (黎洪) (“**Mr. Li**”) has been appointed as the general manager of the Company;
- (b) Mr. Wu Changhai (吳長海) (“**Mr. Wu**”), an executive director of the Company, has been appointed as the standing vice general manager of the Company; and
- (c) Mr. Zhang Chunbo (張春波) (“**Mr. Zhang**”) has been appointed as the vice general manager of the Company.

Each of the above appointment came into effect on 23 June 2017.

### **2. INFORMATION ON MR. LI**

Set out below is the information on Mr. Li.

#### **2.1 Personal particulars**

Mr. Li, aged 50, holds a bachelor degree and a MBA degree. Mr. Li also holds the titles of engineer and senior political work engineer and possesses the qualification of licensed pharmacist. Mr. Li is a specially appointed committee member of the Guangdong Committee of the Chinese People’s Political Consultative Conference. Mr. Li started his career in July 1990. He has served as a director and the chairperson of the board of Guangzhou Baiyunshan Qiao Guang Pharmaceutical Co., Ltd.; a director and the general manager of Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd.; a general

manager, chairperson and secretary of the party committee of Guangzhou Baiyunshan Ming Xing Pharmaceutical Co., Ltd.; a director of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. and an assistant to the general manager of Guangzhou Pharmaceutical Holdings Limited (“**GPHL**”). Mr. Li is currently a member of the party committee of GPHL and a party branch secretary of Guangzhou Haima Pharmaceutical Advertising Co., Ltd..

## **2.2 Term of office**

The term of office of Mr. Li as the general manager commenced from the date on which he was appointed (i.e. 23 June 2017) up to the date on which the members of the new session of the Board (i.e. the 8th session) are elected. On this basis, it is expected that the term of office of Mr. Li as the general manager will be approximately three years. The Company will enter into a service agreement with Mr. Li.

## **2.3 Remuneration**

According to the emoluments policy of the Company, the remuneration of Mr. Li will be determined by the Board after taking into account the Company’s operating results and Mr. Li’s individual performance.

## **2.4 Interests in the shares of the Company within the meaning of Part XV of the SFO**

Set out below are the interests of Mr. Li in the shares of the Company as at the date of this announcement:

<b>Capacity</b>	<b>Number of A shares under the Employee Stock Trust</b>	<b>Approximate percentage in the entire issued share capital of the Company</b>
Beneficial owner	10,000	0.0007

Save as disclosed above, neither Mr. Li nor his associates have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“**SFO**”). The interests of Mr. Li in the A shares of the Company as disclosed in the above are held by the asset manager of the Employee Stock Ownership Scheme (2015) for the benefits of Mr. Li. Details of the Employee Stock Ownership Scheme (2015) were set out in the circular of the Company dated 26 February 2015 and 19 May 2015, respectively.

## **2.5 No other information required to be disclosed**

Save as disclosed in the preceding sections of this announcement, as at the date of this announcement:

- (a) Mr. Li does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company;
- (b) Mr. Li does not have and is not deemed to have any interests in the shares of the Company within the meaning of Part XV of the SFO;
- (c) Mr. Li does not have any directorships held in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas;
- (d) Mr. Li does not hold any position in the Company or other members of the Group; and
- (e) there are no other matters concerning Mr. Li that need to be brought to the attention of the shareholders of the Company and there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Hong Kong Listing Rules**”).

## **3. INFORMATION ON MR. WU AND MR. ZHANG**

Set out below is the information on Mr. Wu and Mr. Zhang.

### **3.1 Information on Mr. Wu**

Particulars on Mr. Wu and further information were set out in Appendix I to the circular of the Company dated 9 May 2017 (“**AGM Circular**”). Save as supplemented by this announcement, the information on Mr. Wu as contained in the AGM Circular remains unchanged from the latest practicable date of the AGM Circular (i.e. 4 May 2017) up to the date of this announcement.

### **3.2 Information on Mr. Zhang**

Mr. Zhang, aged 40, holds a bachelor degree and a master degree of EMBA, and is a druggist. Mr. Zhang graduated from the China Pharmaceutical University in July 2000 and began his career in the same year. In December 2010, he obtained a master degree of EMBA for senior management from the Lingnan (University) College of the Sun Yat-Sen University. He has served as the vice manager of the second zone, assistant to the manager of the sales department, the standing vice general manager of the sales department, the

manager of sales department and the vice director of the marketing department of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited; the vice general manager and the standing vice general manager of Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company (“**Zhong Yi**”). Mr. Zhang has been the vice general manager of the Company since January 2015, and is currently the chairperson and the general manager of Zhong Yi, the chairperson and the general manager of Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. Mr. Zhang has extensive experience in corporate management and marketing.

### **3.3 Term of office**

The terms of office of Mr. Wu as a standing deputy general manager and Mr. Zhang as a deputy general manager both commenced from the date on which Mr. Wu and Mr. Zhang was respectively appointed (i.e. 23 June 2017) up to the date on which the members of the new session of the Board (i.e. the 8th session) are elected. On this basis, it is expected that the term of office of each of Mr. Wu and Mr. Zhang will be approximately three years. The Company will enter into a service agreement with Mr. Wu and Mr. Zhang, respectively.

### **3.4 Remuneration**

According to the emoluments policy of the Company, the remuneration of each of Mr. Wu and Mr. Zhang will be determined by the Board after taking into account the Company’s operating results and his individual performance.

### **3.5 Interests in the shares of the Company within the meaning of Part XV of the SFO**

Set out below are the interests of Mr. Zhang in the shares of the Company as at the date of this announcement:

<b>Capacity</b>	<b>Number of A shares under the Employee Stock Trust</b>	<b>Approximate percentage in the entire issued share capital of the Company</b>
Beneficial owner	10,000	0.0007

Save as disclosed above, neither Mr. Zhang nor his associates have any interest in the shares of the Company within the meaning of Part XV of the SFO. The interests of Mr. Zhang in the A shares of the Company as disclosed in the above are held by the asset manager of the Employee Stock Ownership Scheme (2015) for the benefits of Mr. Zhang. Details of the Employee Stock Ownership Scheme (2015) were set out in the circular of the Company dated 26 February 2015 and 19 May 2015, respectively.

### **3.6 No other information required to be disclosed**

Save as disclosed in the AGM Circular and the preceding sections of this announcement, as at the date of this announcement:

- (a) none of Mr. Wu and Mr. Zhang has any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company;
- (b) none of Mr. Wu and Mr. Zhang has or is deemed to have any interests in the shares of the Company within the meaning of Part XV of the SFO;
- (c) none of Mr. Wu and Mr. Zhang has any directorships held in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas;
- (d) none of Mr. Wu and Mr. Zhang holds any position in the Company or other members of the Group; and
- (e) there are no other matters concerning Mr. Wu or Mr. Zhang that need to be brought to the attention of the shareholders of the Company and there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 26 June 2017

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.*